| Assessment Status |
Rapid Review Complete |
| HTA ID |
23014 |
| Drug |
Olipudase alfa |
| Brand |
Xenpozyme® |
| Indication |
As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B. |
| Rapid review commissioned |
08/03/2023 |
| Rapid review completed |
31/03/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olipudase alfa compared with the current standard of care. |
